A therosclerosis is a chronic inflammatory pathogenic process of arteries, which leads to cardiovascular diseases (CVDs), including myocardial infarction and stroke. 1 Despite current therapies, CVDs remain the number one cause of death in the United States. 2 We and others have previously shown that hyperlipidemia, along with other CVD stressors, such as hyperglycemia and hyperhomocysteinemia, promote atherosclerosis via several mechanisms. These mechanisms include endothelial cell (EC) activation and injury 3, 4 LPC species, including palmitoyl-LPC (16:0), stearoyl-LPC (18:0), and oleoyl-LPC (18:1), were ≈2 times higher in atherosclerotic plaques associated with symptoms than those in asymptomatic plaques in humans.
14 However, whether LPC is induced during early atherogenesis remains unknown.
It was shown 30 years ago that when low-density lipoprotein was incubated with ECs, low-density lipoprotein was oxidized and as much as 40% of the low-density lipoprotein phospholipid was hydrolyzed to LPC by the enzymatic action of phospholipase. 15 It was later found that LPC could potently activate ECs and induce monocyte adhesion by transcriptionally upregulating intercellular adhesion molecule-1 (ICAM-1) gene expression in human umbilical vein ECs (HUVECs). 16 Furthermore, both reactive oxygen species (ROS) inhibitor and intracellular calcium inhibitor could block LPC-induced ICAM-1 gene expression in HUVECs. 17 Moreover, LPC also activated proinflammatory transcription factors, such as nuclear factor-κB (NF-κB) and activator protein-1 (AP-1), in HUVECs. 18 Nevertheless, the source of ROS that contributes to LPC-induced EC activation and the mechanistic links between these cellular signaling events remain unclear.
There are multiple cellular sources of ROS, including mitochondrial electron transport chain, nicotinamide adenine dinucleotide phosphate oxidase (NADPH oxidase), xanthine oxidase, uncoupled nitric oxide synthase, and cytochrome P450. As a major contributor to cellular ROS, mitochondrial ROS (mtROS) are generated from the partial oxygen reduction to form superoxide at complex I and complex III in the mitochondrial electron transport chain. 19 Although mtROS are historically considered to be toxic by-products of mitochondrial metabolism, it has been recently discovered that mtROS are, in fact, signaling molecules that directly contribute to proinflammatory cytokine production, 19 independently of key cytosolic ROS generator, NADPH oxidase. 20 In addition, mtROS production is regulated by several factors, such as mitochondrial membrane potential, mitochondrial Ca 2+ , and mitochondrial proton leak. 19 However, because mtROS and ATP production are both coupled to electron transport chain activity, it still remains unknown how mtROS could be induced independently of ATP synthesis.
Thus, in spite of recent progress, 2 important knowledge gaps exist: first, it remains unknown whether the expression of LPC is increased during early atherosclerosis; second, the intracellular source of ROS, which contributes to LPCinduced aortic EC activation, is unclear. In this study, we test a novel hypothesis that mtROS serve as signaling mediators for LPC-induced EC activation. Using metabolomics analysis and microarray profiling, as well as biochemistry and molecular biology approaches, we found that LPCs were induced in the aorta during early atherosclerosis and that mtROS mediated LPC-induced EC activation. In addition, we uncovered a novel ATP synthesis-uncoupled, but proton leak-coupled, mechanism in driving mtROS production in the cell. Thus, mtROS may serve as a novel target for therapeutic intervention in vascular inflammation and CVDs.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

LPCs Are Induced in the Aorta During Early Atherosclerosis in Mice
To determine whether LPC is involved in early atherosclerosis development, we examined LPC levels in the aortas of apolipoprotein E knockout (ApoE −/− ) mice (an atherosclerotic mouse model) in comparison to those of wild-type control mice. We performed nontargeted metabolomic analysis on the aortas from these mice fed with high-fat diet for 3 weeks ( Figure I in the online-only Data Supplement). Of note, western-type, high-fat diet was used to accelerate atherosclerosis, and we and others have shown previously that in ApoE −/− mice fed with high-fat diet for 3 weeks, plasma cholesterol level tripled, but minimal plaque developed in the aorta. 3, 21 Thus, it serves well as an early atherosclerosis mouse model. We were able to detect 8 different LPC species in the aortas of wild-type and ApoE −/− mice. The 3 most abundant species in the aorta included palmitoyl-LPC (16:0), stearoyl-LPC (18:0), and oleoyl-LPC (18:1). Strikingly, all of the detected LPC species were significantly induced in the aortas of ApoE −/− mice, with the exception of linoleoyl-LPC (18:2) ( Figure 1A ). LPC is produced by the enzymatic action of phospholipase A 2 (PLA 2 ) on phosphatidylcholine; and the PLA 2 superfamily enzyme members are critically involved in atherosclerosis. 11, 22 For these reasons, we also examined the gene expression changes of all the PLA 2 superfamily enzymes between ApoE −/− mice and wild-type mice using microarray analysis. The results showed that Pla2g7 (also known as lipoprotein-associated PLA 2 ) and Pla2g4c were significantly induced in the aortas of ApoE −/− mice in early atherosclerosis ( Figure 1B ; Table I in the online-only Data Supplement) . Notably, the expression levels of 3 housekeeping genes were within the range of 0.97 to 1.06, suggesting the high quality of our microarray analysis and the specificity of PLA 2 upregulation. It is possible that aortic LPC could be increased because of increased substrate availability in ApoE −/− mice. However, it is unlikely to be the case because several long-chain fatty acids, including palmitate (16:0), stearate (18:0), and oleate 
LPC Induces mtROS Independently of NADPH Oxidase, in Human Aortic ECs
Next, we hypothesized that the induction of aortic LPC could contribute to atherosclerosis development by promoting aortic EC activation. It should be noted that lesional macrophages are also present in early atherosclerosis, but our current study focuses on investigating the role of LPC in aortic EC activation. It has been previously demonstrated that LPC induced EC activation in HUVECs. 16 In addition, LPC-induced EC activation in HUVECs could be blocked by diphenyleneiodonium, 17 which inhibits ROS generation from mitochondria as well as NADPH oxidase, the latter of which being a major cytosolic ROS generator. Thus, the intracellular source of ROS contributing to LPC-induced human aortic ECs (HAEC) activation remains to be specified. To examine this issue, we first compared the effects of LPC on the production of mtROS and cytosolic ROS in HAECs simultaneously by using electron spin resonance method. We found that 10 µmol/L palmitoyl-LPC (16:0) quickly induced mtROS production in 30 minutes, which lasted for at least 6 hours and decreased after 24 hours (Figure 2A and 2B ). In addition, LPC induced cytosolic ROS in a similar manner, but to a lesser degree ( Figure 2B ). Importantly, a specific NADPH oxidase inhibitor, VAS-2870, did not prevent LPC-induced mtROS in HAECs, but rather further increased it ( Figure 2C ). Of note, VAS-2870 treatment alone also significantly induced mtROS in HAEC, suggesting that mtROS may be induced to compensate for the loss of cytosolic ROS in the cell. It is possible that VAS-2870 itself may have stimulated mtROS production besides inhibiting NADPH oxidase. However, it is unlikely to be the case because another specific NADPH oxidase inhibitor, VAS3947, similarly induced mtROS (data not shown). Furthermore, mtROSinducer, Antimycin A, induced both mtROS and cytosolic ROS, whereas NADPH oxidase activator, phorbol myristate acetate, only induced cytosolic ROS ( Figure 2D ). Taken together, these results have demonstrated that LPC-induced mtROS are located upstream of the pipeline in generating cytosolic ROS.
To confirm the results from electron spin resonance, we used another specific mtROS fluorescence probe, MitoSOX, combined with the use of flow cytometry and found that LPC dose-dependently increased mtROS production in HAECs ( Figure 2E ). Higher dosage of LPC (40 μmol/L), however, did not further induce mtROS but was cytotoxic ( Figure 2E and 2F). In addition, we found that the induction of mtROS is a common feature shared by the LPC family members because all the 3 major LPC species, including LPC (16:0), LPC (18:0), and LPC (18:1), similarly induced mtROS production in HAECs ( Figure 2G ). Because LPC (16:0) was the most abundantly expressed aortic LPC species ( Figure 1A ), 10 μmol/L LPC (16:0) was used hereafter in this study. Finally, we used a third method, fluorescence microscopy, and confirmed that LPC induced mtROS in HAECs ( Figure 2H ). Collectively, these results indicate that 3 major LPC species, upregulated in early atherosclerotic aortas ( Figure 1A ), could all induce mtROS in HAECs. Although high levels of mtROS induced by a high concentration of LPC are associated with EC death, moderate levels of mtROS stimulated by 10 µmol/L LPC could serve as signaling molecules for EC activation.
Mitochondrial Ca 2+ Entry Mediates LPC-Induced mtROS Production by Increasing Mitochondrial Proton Leak and Oxygen Reduction in HAECs
mtROS production is regulated by several factors, such as the metabolic state of mitochondria, mitochondrial membrane potential, and mitochondrial Ca 2+ influx. 19, 23 Because previous ) mice were fed with high-fat diet for 3 wk before they were euthanized. Aortas were collected from these mice for metabolomics analysis (A) and microarray analysis (B). A, Aortic LPC species were induced during early atherosclerosis. Relative changes of aortic LPC between WT and ApoE −/− were shown (n=8 per group). B, LPC-generating enzymes, including Pla2g4c and Pla2g7, were induced in the aortas during early atherosclerosis. Volcano plot was presented which showed fold change and statistical P value of expression changes of phospholipase A 2 superfamily members and 3 housekeeping genes (Actb, Gapdh, and Nono) between ApoE −/− mice and WT mice (n=5 per group; solid triangle, significantly increased phospholipase A 2 [PLA 2 ] genes; gray diamond, unchanged PLA 2 genes; empty circle, control housekeeping genes). For all panels, values represent mean±SEM. NS indicates not significant. *P<0.05; **P<0.01; ***P<0.001. studies reported that LPC could induce cytosolic Ca 2+ levels 24 and that Ca 2+ influx into mitochondria is a positive regulator of mitochondrial O 2 reduction rates, 25 we hypothesized that LPC-induced Ca 2+ entry into the mitochondria could lead to increased mtROS production. First, we examined the effects of LPC on cytosolic and mitochondrial Ca 2+ levels simultaneously using confocal microscopy. The results showed that LPC dramatically induced cytosolic Ca 2+ , which were quickly followed by mitochondrial Ca 2+ induction ( Figure 3A and 3B). The peak response of mitochondrial Ca 2+ entry was similar to that of cytosolic Ca
2+
, and both signals lasted for at least 5 minutes ( Figure 3B and 3C). These results indicate that LPC induces mitochondrial Ca 2+ entry from cytosol. Next, we hypothesized that LPC-induced mitochondrial Ca 2+ entry could lead to mtROS production in HAECs. To examine this, we used ruthenium red (RR), which is a mitochondrial calcium uniporter (MCU) inhibitor that can block Ca 2+ entry into the mitochondria. We found that RR completely abolished LPC-induced mtROS production ( Figure 4A ), indicating that mitochondrial Ca 2+ entry mediates LPC-induced mtROS in HAECs. To determine how LPC-induced mitochondrial Ca 2+ entry accelerated mtROS production, we utilized the Seahorse XF96 Analyzer to assess mitochondria functions. The Seahorse XF analyzer could measure 6 different mitochondrial parameters, including mitochondrial O 2 reduction rate, nonmitochondrial O 2 reduction rate, proton leak, ATP production, maximal respiration, and spare respiratory capacity ( Figure II in the online-only Data Supplement). We found that LPC significantly induced mitochondrial O 2 reduction rate but did not affect nonmitochondrial O 2 reduction rate ( Figure 4B and 4C), which correlated with our previous findings that LPC-stimulated ROS originated from mitochondria, but not from cytosol ( Figure 2 ). In addition, the MCU inhibitor, RR, significantly inhibited LPC-induced mitochondrial O 2 reduction rates ( Figure 4C ), correlating with the previous findings that mitochondrial Ca 2+ entry mediates LPC-induced mtROS in HAECs ( Figure 4A ). LPC also significantly increased maximal respiration rates, but it did not change spare respiratory capacity of mitochondria ( Figure 4C ), which suggested that LPC-induced maximal O 2 reduction increase was mainly because of increased basal O 2 reduction. The rate of mitochondrial O 2 reduction is coupled to the rates of ATP production and proton leak ( Figure II in the online-only Data Supplement). Mitochondrial proton leak is the re-entry of protons from the intermembrane space into the mitochondrial matrix independent of ATP synthesis, which usually leads to a decrease in mitochondrial membrane potential (ΔΨm). 25 Interestingly, we found that LPC significantly induced proton leak but not ATP production and that LPC-induced proton leak could be blocked by the MCU inhibitor, RR ( Figure 4C ). Moreover, LPC did not change ΔΨm in HAECs ( Figure 4D ), whereas chemical mitochondrial membrane uncoupler, FCCP (carbonyl cyanidep-trifluoromethoxyphenylhydrazone), significantly decreased ΔΨm. These results suggest the following: first, LPC-induced mitochondrial Ca 2+ entry preferentially stimulates proton leak but not ATP synthesis, suggesting that LPC at low dose is not an energy-generating stimulus in ECs; second, LPC-induced proton leak is used by EC for the induction of O 2 reduction in the electron transport chain; third, mtROS are increased in response to LPC stimulation and reversed by MCU inhibitor RR, and fourth, LPC-induced proton leak is equivalent to the proton efflux into intermembrane space, so that mitochondrial membrane potential is not affected. Taken together, these results indicate that LPC induces mitochondrial Ca 2+ entry, which increases ATP synthesis-uncoupled, but proton leakcoupled, mtROS ( Figure 4E ).
Because ROS production in mitochondria is determined by the rates of both mtROS production and disposal, 19 we also investigated the effects of LPC on regulating the expression of mitochondrial antioxidant superoxide dismutase 2 and uncoupling molecules including uncoupling protein 3 and adenine nucleotide translocator. We found that LPC did not regulate the expression of superoxide dismutase 2 and uncoupling protein 3, although there was a trend of adenine nucleotide translocator induction after LPC stimulation ( Figure III in the online-only Data Supplement). Adenine nucleotide translocator, also known as the ADP/ATP translocator, exports ATP from the mitochondrial matrix, imports ADP into the matrix, and also mediates both basal and inducible proton conductance. The induction of adenine nucleotide translocator by LPC correlated with the findings that LPC induced mitochondrial proton leak in HAECs ( Figure 4C ).
mtROS Contribute to LPC-Induced Upregulation of ICAM-1 and Other EC Activation-Related Genes by Regulating Nuclear Binding of AP-1
To determine the downstream effects of LPC-induced mtROS in ECs, we determined the effects of LPC in regulating EC-related gene expressions by performing Human Endothelial Cell Biology polymerase chain reaction (PCR) array profiling. HAECs were stimulated by LPC with or without a specific mtROS scavenger, MitoTEMPO. PCR array was performed afterward to screen for the changes of 84 genes related to EC functions, including vessel tone, angiogenesis, EC activation, and EC injury. We were able to detect the expressions of 57 genes in both control and LPCtreated HAECs. Among these 57 expressed genes, we found that 34 genes were induced >1.2-fold by LPC, and 3 genes were decreased >1.2-fold (Table II in the online-only Data Supplement). More importantly, we found that 14 out of these 34 LPC-induced genes (41.2%), such as ICAM-1, plasminogen activator, tissue, interleukin 6, and matrix metalloproteinase-2, could be blocked by cotreatment of mtROS inhibitor, MitoTEMPO. Importantly, the expression of EC adhesion molecule, ICAM-1, was the most sensitive gene in response to mtROS scavenging ( Figure 5A ). By using real-time polymerase chain reaction and Western blots, we confirmed that LPC increased ICAM-1 RNA and protein expression, which could be inhibited by MitoTEMPO cotreatment (Figure 5B and 5C). Furthermore, we performed monocyte adhesion assay and showed that LPC-treated HAECs had increased their adhesion to untreated monocytes, which was inhibited by MitoTEMPO ( Figure 5D ). Taken together, these results demonstrate that mtROS are required for LPC-induced EC activation by regulating the mRNA and protein expressions of certain EC biology-related genes, including ICAM-1. Transcription factor-binding sites of NF-κB and AP-1 have been previously identified in the promoter region of ICAM-1 26 ( Figure 6A ). In addition, LPC has been shown to increase the nuclear translocation of NF-κB and AP-1 in HUVECs. 18 Thus, we hypothesized that LPC-induced mtROS contribute to the nuclear bindings of proinflammatory transcription factors to the promoter of ICAM-1 in HAECs, which leads to ICAM-1 upregulation. Using electrophoretic mobility shift assay, we showed that LPC potently induced nuclear translocation of AP-1 but weakly induced NF-κB in HAECs ( Figure 6B and 6C) . In addition, cotreatment of MitoTEMPO almost completely abolished LPC-induced AP-1 but not NF-κB nuclear binding. These results correlated well with our previous finding that AP-1 mediated LPC-induced EC activation. 3 Moreover, by performing a literature search, we found that out of the 14 upregulated genes that were the targets of LPC-induced mtROS ( Figure 5A ), 12 genes, including ICAM-1, were also previously proposed to be the downstream targets of AP-1 or ROS pathway (Table III in 
mtROS Inhibition Suppresses EC Activation and Monocyte Recruitment Into the Aorta During Early Atherosclerosis In Vivo
To examine whether mtROS contribute to EC activation during early atherosclerosis in vivo, we implanted the ALZET osmotic minipumps containing either saline control or MitoTEMPO (1500 μg/kg/d) subcutaneously into 8-weekold ApoE −/− mice before they were put on a high-fat diet for another 3 weeks. We determined their EC activation status afterward by examining leukocyte rolling and adhesion to the endothelium in cremaster muscle vessels using intravital microscopy. We found that MitoTEMPO significantly inhibited leukocyte rolling and adhesion to the endothelium on the postcapillary venule wall ( Figure 7A and 7B ). Of note, there was no difference in the venule diameters between the 2 groups ( Figure 7C ), suggesting that MitoTEMPO did not significantly change the venule diameters. In addition, we did not detect any leukocyte rolling or adhesion in the arterioles of the ICAM-1) . A, Putative AP-1 and nuclear factor-κB (NF-κB)-binding site in the promoter of ICAM-1. B and C, mtROS inhibitor MitoTEMPO blocked LPC-induced nuclear AP-1 binding. HAECs were treated with vehicle or LPC (10 μmol/L) for 1 h with or without MitoTEMPO (1 μmol/L) 1-h preincubation, and nuclear proteins were collected afterward for electrophoretic mobility shift assay (EMSA). Two micrograms of nuclear proteins were used for AP-1 EMSA (B) and 5 μg nuclear proteins were used for NF-κB EMSA (C). Representative images from 3 independent experiments were shown. cremaster muscle (data not shown) because of the rapid movement of blood cells within these vessels, as shown previously. 27 Similarly, the high blood flow speeds and high pulse vibrations in middle and aortic arteries make the current technology of intravital microscope unsuitable in determining in vivo leukocyte rolling and adhesion to the endothelium in aortic arteries. 28 To determine whether MitoTEMPO could decrease the recruitment of monocytes into the aortas of ApoE −/− mice, we prepared aortic single cell suspensions from these mice and performed flow cytometric analysis with fluorescenceconjugated antibodies staining for Indo-1 (dead cell), CD45 (leukocyte), CD11b (monocyte), and Ly6c (inflammatory or resident monocyte), as we reported previously 6 ( Figure 7D ). The results showed that MitoTEMPO significantly decreased the recruitment of CD45 
Discussion
Atherosclerosis is a chronic inflammatory disease that is a major pathogenic process underlying the development of coronary heart disease, stroke, and peripheral vascular disease. In spite of recent progress, novel anti-inflammatory strategies are still in urgent need for prevention and treatment of atherosclerotic CVD. 29 LPCs are a group of endogenous proinflammatory lipids considered to be a causative factor for atherosclerosis. For this reason, inhibitors of sPLA 2 and Lp-PLA 2 , the key enzymes responsible for the generation of LPC, have been developed in the hope of developing novel anti-inflammatory therapies against atherosclerosis. 29 The beneficial effects of sPLA 2 inhibitor (Varespladib) and Lp-PLA 2 inhibitor (Darapladib) have been demonstrated in atherosclerotic animal models 13, 30 and human phase 2 clinical trials. 31, 32 However, 3 recent phase 3 clinical trials failed to show their therapeutic efficacy. [33] [34] [35] One possibility that may explain these failures is related to the fact that LPC also plays important physiological roles, such as stimulating insulin release from pancreatic β cells 36 and transporting essential fatty acids. 37 For this reason, targeting the pathogenic downstream effects of LPC, instead of blocking the production of LPC itself, may lead to the development of better therapeutics. Along this line, our approaches using metabolomics and transcriptomics in this study demonstrated that 7 out of 8 detected LPC species were induced in the aorta of early atherosclerotic mice, presumably because of increased expression of PLA 2 in the aorta. More importantly, we found that proatherogenic lipid, LPC, via a mtROS-mediated mechanism, induced EC activation, which is an initiation step of atherogenesis. Therefore, blocking excessive mtROS production downstream of LPC might protect arteries against atherogenesis. This idea is supported by previous findings reporting that various other vascular stressors, including oxidized low-density lipoprotein, glucose, angiotensin II, hypoxia, and proinflammatory cytokines, also induced mtROS production in ECs. 19 In addition, pharmacological drugs, such as statins, metformin, resveratrol, and cannabidiol, could inhibit glucose-induced mtROS production in ECs. 19 Moreover, it has been shown previously that ApoE −/− mice deficient in superoxide dismutase 2 gene, which scavenges mtROS, displayed accelerated atherogenesis. 38 EC-specific overexpression of thioredoxin 2, another mitochondrial antioxidant enzyme, improved endothelial function and reduced atherosclerosis development in ApoE −/− mice. 39 Collectively, we and others have demonstrated a critical proatherogenic role for mtROS in EC activation during early atherosclerosis. Notably, LPC could also activate macrophages besides promoting EC activation 11 and diminishing mtROS in macrophages reduced lesion development in atherosclerotic mice. 40 Further study is needed to determine the role of LPC-induced mtROS in lesional macrophages during the development of atherosclerosis.
Previous studies have reported that LPC could induce nicotinamide adenine dinucleotide oxidase (mitochondrial)/ NADPH oxidase (cytosolic)-related ROS in ECs. 41 In addition, it was found that LPC-induced ROS was more prominent in mitochondria and much less abundant in cytosol. 24 It has also been shown that mitochondria, rather than NADPH oxidase, was the major source of inflammatory ROS in monocytes. 20 Along the same line, we identified that LPC-induced mtROS production was independent of NADPH oxidase in ECs.
Even when there is ample oxygen, ECs rely heavily on glycolysis for their ATP demand, yet ECs contain functional mitochondria and little is known about the role of mitochondria in endothelium. 42 By using the novel, state-of-art mitochondrial Seahorse XF96 analyzer for assaying mitochondrial functions, we demonstrate that when ECs are activated, LPC induces mtROS by accelerating electron transport chain and proton efflux, which is uncoupled from ATP synthesis by 2+ then stimulates mitochondrial electron transport chain and proton leak without affecting ATP synthesis and mitochondrial membrane potential. As a result, mitochondrial reactive oxygen species (mtROS) are specifically induced without causing mitochondria injury. LPC-induced mtROS could then be released to the cytosol, where they regulate nuclear binding of activator protein-1 (AP-1) to the promoter of intercellular adhesion molecule-1 (ICAM-1) and other genes, contributing to endothelial activation. Anterograde signaling describes signal transduction from cytosol to mitochondria, and retrograde signaling describes signal transduction from mitochondria to cytosol and nucleus. Right, LPC induces ATP-uncoupled, but proton leak-coupled, mtROS. ΔΨm indicates mitochondrial membrane potential.
simultaneously accelerating proton leak. Thus, we propose that one of the major functions of mitochondrial proton leak in ECs may be fine-tuning mtROS generation for cell-signaling purpose, such as endothelial activation. By doing this, in response to proatherogenic/proinflammatory stimuli including LPC, ECs could upregulate mtROS production without affecting ATP level and EC survival (Figure 8 ). This hypothesis is supported by the findings that mtROS were involved in regulating important physiological endothelial functions, such as hypoxia adaptation and angiogenesis effects, and in activating proinflammatory signaling pathways in response to various vascular stressors. 19 Although controversies exist regarding what the real LPC receptor(s) is in the cell, LPC has been shown to stimulate cytosolic Ca 2+ in different cell types. 11 In addition, it has been shown that LPC induced cellular Ca 2+ uptake from an extracellular source via transient receptor potential vanilloid 2 channel. 43 Interestingly, RR, which was used in this study for inhibiting MCU for mitochondrial Ca 2+ entry, could also potently inhibit transient receptor potential vanilloid 2 for cytosolic Ca 2+ entry. Future studies are needed to determine the roles of MCU and transient receptor potential vanilloid 2 in LPC-induced mtROS production.
To summarize (Figure 8 ), our study suggests that during early atherosclerosis, aortic LPCs are induced, presumably because of increased enzyme expression of Pla2g4c and Pla2g7. LPC then induces Ca 2+ entry from cytosol to mitochondria, where it drives ATP synthesis-uncoupled, but proton leak-coupled, mtROS. LPC-induced mtROS then regulate nuclear binding of AP-1 to the promoters of ICAM-1 and other EC activation-related genes, contributing to endothelial activation, monocyte adhesion to ECs, and monocyte recruitment into aorta. These findings are important, as they have improved our understanding of the molecular mechanisms of hyperlipidemia stimuli-induced EC activation in early atherogenesis. Such findings may, in turn, lead to the development of novel therapies, such as mitochondria-targeting antioxidant, which might greatly improve the outcome of CVDs.
